COVID-19 Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0C5MT
|
|||
Drug Name |
Rintatolimod
|
|||
Synonyms |
Ampligen
|
|||
Drug Type |
Protein/peptide drug
|
|||
Indication | Coronavirus Disease 2019 (COVID-19) | Phase 1/2 | [1] | |
Other Indication | Chronic fatigue syndrome | phase 3 | [2] | |
Therapeutic Class |
Antiviral Agents
|
Target | Top | |||
---|---|---|---|---|
Target(s) | HUMAN toll-like receptor 3 (TLR3) | Target Info | Agonist | [3], [4] |
Rintatolimod is a restricted Toll-Like Receptor 3 (TLR3) agonist lacking activation of other primary cellular inducers of innate immune and also activates interferon induced proteins that require dsRNA for activity (e.g. adenylate synthetase, protein kinase R). Evidence shows that combination of interferon alfa with a viral mimic such as ampligen can be an effective strategy against COVID-19. |
References | Top | |||
---|---|---|---|---|
1 | ClinicalTrials.gov (NCT04379518) Rintatolimod and IFN Alpha-2b for the Treatment of Mild or Moderate COVID-19 Infection in Cancer Patients. U.S. National Institutes of Health. | |||
2 | ClinicalTrials.gov (NCT00215813) Ampligen in Chronic Fatigue Syndrome. U.S. National Institutes of Health. | |||
3 | Efficacy of rintatolimod in the treatment of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). Expert Rev Clin Pharmacol. 2016 Jun;9(6):755-70. | |||
4 | AIM ImmunoTech Announces FDA Authorization for First Human Ampligen Trial in COVID-19 Patients with Cancer; Provides Corporate Business Update for the First Quarter of 2020 |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.